LogicBio Therapeutics (OTCMKTS:LOGC) Sees Strong Trading Volume – Here’s What Happened

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) shares saw unusually-high trading volume on Monday. 643,184 shares traded hands during trading, an increase of 383% from the average daily volume of 133,170 shares. The stock last traded at $15.00 and had previously closed at $15.15.

LogicBio Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.29, a current ratio of 1.87 and a quick ratio of 1.24. The stock’s fifty day moving average is $14.80 and its 200-day moving average is $10.40. The stock has a market cap of $647.08 million, a PE ratio of -19.38 and a beta of 2.11.

LogicBio Therapeutics (OTCMKTS:LOGC) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.25). The company had revenue of $32.20 million for the quarter, compared to analysts’ expectations of $23.31 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc. was a biotechnology company focused on developing genomic medicines for rare diseases, particularly conditions affecting children. Its research centered on approaches intended to address the underlying genetic causes of disease. The company developed GeneRide, a genome-editing platform designed to integrate therapeutic genetic material into a patient’s DNA. Its lead program, LB-001, was investigated for methylmalonic acidemia, a rare inherited metabolic disorder. LogicBio also worked on sAAVy, a platform for discovering and developing adeno-associated virus vectors for gene delivery.